PT-141 Therapy
What is PT-141?
PT-141 (Bremelanotide, brand name Vyleesi) is a melanocortin receptor agonist FDA-approved for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike other sexual dysfunction treatments that act on the vascular system, PT-141 works through the central nervous system, specifically the melanocortin receptors in the brain that regulate sexual arousal and desire.
Benefits & Uses
Treats low sexual desire in both men and women, works through the central nervous system rather than the vascular system, effective for conditions unresponsive to PDE5 inhibitors, FDA-approved with established safety profile.
Potential Side Effects
Nausea (most common, especially with first use), flushing, headache, injection site reactions. May cause temporary increases in blood pressure. Not recommended for use with certain cardiovascular conditions.
Find PT-141 Providers Near You
Browse 72 providers offering PT-141 therapy in our directory.
Browse ProvidersFrequently Asked Questions
Treats low sexual desire in both men and women, works through the central nervous system rather than the vascular system, effective for conditions unresponsive to PDE5 inhibitors, FDA-approved with established safety profile.
PT-141 therapy typically costs between $150 and $400 per month, though prices vary by provider, location, and dosage.
PT-141 has an FDA status of "FDA-approved". It has been approved by the FDA for specific indications. Your provider can explain the approved uses and any off-label applications.
Nausea (most common, especially with first use), flushing, headache, injection site reactions. May cause temporary increases in blood pressure. Not recommended for use with certain cardiovascular conditions.
PeptideProbe lists 72 providers offering PT-141 therapy. Use our directory to search by location, filter by telehealth availability, and compare providers.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.